Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab with Nab-Paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
NCT03086369Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2017
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of olaratumab (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Dose Limiting Toxicities and Overall Survival up To 29 Months. Started Jun 2017; status: completed.
02
Drugs
olaratumab
Beyond the preview
Go deeper on NCT03086369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086369.